Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

PURPOSE: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti–programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated significantly improved progression-free survival (PFS) for nivolumab and relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo Antonio, Lipson, Evan J., Dummer, Reinhard, Larkin, James, Long, Georgina V., Sanborn, Rachel E., Chiarion-Sileni, Vanna, Dréno, Brigitte, Dalle, Stéphane, Schadendorf, Dirk, Callahan, Margaret K., Nyakas, Marta, Atkinson, Victoria, Gomez-Roca, Carlos Alberto, Yamazaki, Naoya, Tawbi, Hussein A., Sarkis, Naomey, Warad, Deepti, Dolfi, Sonia, Mitra, Priyam, Suryawanshi, Satyendra, Grob, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431305/
https://www.ncbi.nlm.nih.gov/pubmed/36780608
http://dx.doi.org/10.1200/JCO.22.02072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431305/
https://www.ncbi.nlm.nih.gov/pubmed/36780608
http://dx.doi.org/10.1200/JCO.22.02072

Ejemplares similares